New York, NYNCT07450859Now EnrollingIRB Ready

Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trial in New York, NY

Access cutting-edge pancreatic ductal adenocarcinoma (pdac) treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by BicycleTx Limited

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access pancreatic ductal adenocarcinoma (pdac) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic ductal adenocarcinoma (pdac) treatment provided free

Apply for This New York Location

Check if you qualify for this pancreatic ductal adenocarcinoma (pdac) clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Pancreatic Ductal Adenocarcinoma (PDAC) Study in New York

This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.

Sponsor: BicycleTx Limited

Who Can Participate

Inclusion Criteria

At least 18 years of age at the time of signature of the informed consent form
Measurable disease as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Life expectancy of at least 12 weeks
Histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC)
Participants must have failed only 1 prior line of therapy with evidence of radiographic progression. Neoadjuvant or adjuvant systemic therapy may count as the first line if the participant progressed less than 6 months from the end of systemic therapy. Prior treatment with KRAS inhibitors is permitted
Participants must have sufficient tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers
Adequate organ function (hematologic, renal, and hepatic)
Negative pregnancy test for participants of childbearing potential (POCBP)
Must be willing and able to comply with the protocol and study procedures

Exclusion Criteria

Chemotherapy or radiotherapy within 14 days prior to the first dose of study treatment
Experimental treatments within 28 days or 5 half-lives, whichever is longer, of first dose of nuzefatide study treatment
Prior treatment with taxane therapy (e.g., paclitaxel) for pancreatic cancer or prior treatment with any MMAE-containing agent
Known microsatellite instability-high (MSI-H) status and are eligible for immune checkpoint inhibitor therapy
Prior toxicities must have resolved to Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0
Untreated central nervous system (CNS) metastases Note: Additional protocol defined Inclusion/Exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07450859) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Ductal Adenocarcinoma (PDAC) Treatment Options in New York, NY

If you're searching for pancreatic ductal adenocarcinoma (pdac) treatment options in New York, NY, this clinical trial (NCT07450859) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic ductal adenocarcinoma (pdac) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic ductal adenocarcinoma (pdac) clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in New York, NY

See all pancreatic cancer clinical trials recruiting in New York — not just this study.

Browse Pancreatic Cancer Trials in New York

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY